IDH抑制剂治疗复发高级别胶质瘤的单中心经验
中位无进展生存期为6.8个月,IDH抑制剂治疗后中位总生存期为20.7个月,未达到中位总生存。未接受初始化疗的患者总生存和无进展生存均更长。
要点
- IDH抑制剂在复发IDH突变型高级别胶质瘤中耐受性良好。
- 中位无进展生存期6.8个月,IDH抑制剂后中位总生存期20.7个月。
- 未接受初始化疗者总生存(p=0.032)和无进展生存(p=0.041)更长。
核心结论
- IDH抑制剂在既往接受过DNA损伤剂治疗的IDH突变型高级别胶质瘤患者中耐受性良好。
- 中位无进展生存期超过6个月在该患者群体中令人鼓舞,可能归因于IDH抑制剂在复发高级别胶质瘤中的抗肿瘤活性。
研究设计与样本
- 共纳入23例患者,其中65.2%为男性;星形细胞瘤14例(60.9%),WHO 3级少突胶质细胞瘤9例(39.1%),其中4例为WHO 4级星形细胞瘤,10例为WHO 3级星形细胞瘤。
- 20例患者在推荐IDH抑制剂时存在强化病灶;1例接受enasidenib,17例接受ivosidenib,5例接受vorasidenib;初始接受ivosidenib的患者中9例换用vorasidenib。
- 所有患者在开始IDH抑制剂前均接受过手术、放疗和化疗。
主要发现
- 中位总生存未达到,IDH抑制剂治疗后总生存期为20.7个月。
- 未接受初始化疗的患者总生存更长(p = 0.032)。
- 中位无进展生存期为6.8个月,在不同肿瘤类型、性别或复发次数间无差异,但在未接受初始化疗的患者中更长(p = 0.041)。
- 2例患者因副作用停药,分别为肝酶升高(n = 1)和腹泻(n = 1)。
临床怎么用
- 对于既往接受过手术、放疗和化疗的复发IDH突变型高级别胶质瘤患者,可考虑使用FDA批准的IDH抑制剂。
- 治疗期间需监测肝酶升高和腹泻等不良反应。
局限性
- 回顾性单中心研究,样本量较小(23例)。
- 中位总生存未达到,随访时间可能不足以评估最终生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of IDH inhibitors in recurrent high-grade gliomas (HGG) is not well described. We present the outcomes of patients with HGG that were treated with these agents at our institution. METHODS: We reviewed patients with recurrent IDH-mutant HGG treated with FDA approved IDH inhibitors (ivosidenib, enasidenib, and vorasidenib) from December 2019 to December 2024 at the University of Texas MD Anderson Cancer Center. RESULTS: 23 patients were identified of which 65.2% were male. Tumors included astrocytoma (n = 14, 60.9%) and WHO grade 3 oligodendroglioma (n = 9, 39.1%), with four patients having a WHO grade 4 astrocytoma and 10 a WHO grade 3 astrocytoma. Twenty patients had enhancing disease at the time an IDH inhibitor was recommended. One patient was treated with enasidenib, 17 with ivosidenib, and 5 with vorasidenib. Of those initially treated with ivosidenib, 9 were switched to vorasidenib. Two patients discontinued the drugs due to side effects, that included elevated liver enzymes (n = 1), and diarrhea (n = 1). All patients had received prior surgery, radiation, and chemotherapy before starting an IDH inhibitor. Median overall survival (OS) was not reached. OS after IDH inhibitor was 20.7 months and was longer in patients that had not received initial chemotherapy (p = 0.032). Median progression-free survival (PFS) was 6.8 months and was not different between tumor type, sex, or number of recurrences, but was longer in patients that did not receive initial chemotherapy (p = 0.041). CONCLUSION: IDH inhibitors were well tolerated in patients with IDH-mutant HGG previously treated with DNA-damaging agents. A median PFS longer than 6 months is encouraging in this patient population and may be due to antitumor activity of IDH inhibitors in recurrent HGG.
引用
- Garcia CR, Highsmith K, Knight S, et al. Single center experience of IDH inhibitors in recurrent high-grade gliomas. J Neurooncol. 2025. PMID: 40748516. doi:10.1007/s11060-025-05183-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。